124 completed, 49 recruiting, 48 active not recruiting, 19 terminated. 126 Phase 2, 90 Phase 3, 40 Not applicable, 8 Phase 1.
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine - Biliary Tract Cancer (BTC) | Phase 3 | Not yet recruiting | UNICANCER | 990 | 2027-01-02 | 2026-08-04 |
| Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate. Immuno-PET - Locally Advanced or Metastatic Breast Cancer | Phase 2 | Not yet recruiting | UNICANCER | 30 | 2026-12-31 | 2026-07-31 |
| Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndrome INVITRO DIAGNOSTIC TESTS AND COLONOSCOPY - Lynch Syndrome | Not applicable | Not yet recruiting | UNICANCER | 2000 | 2026-12-01 | 2026-08-03 |
| Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck Zanzalintinib - Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence | Phase 2 | Not yet recruiting | UNICANCER | 51 | 2026-10-01 | 2026-07-06 |
| Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer. Tumor assessment, Completion of Quality-of-life questionnaires, ECG - Metastatic Invasive Breast Cancer | Phase 3 | Not yet recruiting | UNICANCER | 370 | 2026-09-25 | 2026-07-21 |
| Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs. prifetrastat monotherapy for 15 days then combination with fulvestrant, prifetrastat in combination with fulvestrant - Metastatic (Stage IV) Melanoma | Phase 2 | Not yet recruiting | UNICANCER | 51 | 2026-09-18 | 2026-08-03 |
| Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer Sacituzumab Govitecan / Trastuzumab Deruxtecan - Triple Negative Breast Neoplasms, Neoplasm Metastasis | Phase 2 | Not yet recruiting | UNICANCER | 260 | 2026-09-01 | 2026-08-03 |
| Blood Biomarkers Based Screening for HPV-driven OPC HPV16-E6 serology and HPV ctDNA - Head and Neck Squamous Cell Carcinoma, Anal Cancer | Not applicable | Not yet recruiting | UNICANCER | 10000 | 2026-09-01 | 2026-05-26 |
| SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer Lymphatic mapping with SPECT-CT, Bilateral neck radiotherapy, Ipsilateral neck radiotherapy & SPECT-CT guided contralateral neck radiotherapy - Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Cancers | Not applicable | Not yet recruiting | UNICANCER | 128 | 2026-09-01 | 2026-07-21 |
| Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases Ivonescimab, Bevacizumab, FOLFIRI Protocol - Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | UNICANCER | 130 | 2026-08-31 | 2026-05-19 |
| Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels Pembrolizumab, Cemiplimab - Non Small Cell Lung Cancer (Squamous or Non Squamous) | Phase 2 | Recruiting | UNICANCER | 275 | 2026-08-21 | 2026-09-25 |
| Immunotherapy Master Trial for Advanced Cancers METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each - Advanced / Metastatic Solid Tumors, Advanced Malignancy | Phase 2 | Recruiting | UNICANCER | 275 | 2026-08-21 | 2026-09-29 |
| Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old FOLFOX4s, Short Course Radiotherapy - Locally Advanced Rectal Adenocarcinoma | Phase 3 | Not yet recruiting | UNICANCER | 160 | 2026-07-24 | 2026-07-24 |
| Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test Capecitabine, Oxaliplatin, Folfirinox - Colorectal Cancer | Phase 3 | Active not recruiting | UNICANCER | 2450 | 2026-07-20 | 2026-07-22 |
| Skipping Hormone Therapy in Low-Risk Early Breast Cancer Removing Endocrine Therapy - Breast Cancer (Early Breast Cancer) | Phase 2 | Recruiting | UNICANCER | 700 | 2026-07-06 | 2026-10-05 |
| Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers mFOLFOX regimen, Mitazalimab - Biliary Tract Cancer (BTC) | Phase 2 / Phase 3 | Not yet recruiting | UNICANCER | 160 | 2026-07-01 | 2026-02-27 |
| Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease Arterial catheter infusion chemotherapy, IV Chemotherapy (Regimen 1) - Colorectal Adenocarcinoma Metastatic in the Liver, Colorectal Cancer | Phase 3 | Not yet recruiting | UNICANCER | 272 | 2026-07-01 | 2026-05-26 |
| Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocrine therapy or endocrine therapy alone, In the control arm, the treatment will be as standard of care : chemo-endocrine therapy - Early Breast Cancer, Premenopausal Breast Cancer | Phase 3 | Recruiting | UNICANCER | 3380 | 2026-06-26 | 2026-07-31 |
| Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma Best Supportive Care, Balstilimab, Botensilimab - Colorectal Cancer | Phase 3 | Terminated | Canadian Cancer Trials Group | 21 | 2026-03-31 | 2026-07-16 |
| Evaluation of an Online Intervention to Educate Women at High Risk of Breast Cancer on How to Help Reduce Their Risk. Intervention - Breast Cancer | Not applicable | Recruiting | UNICANCER | 1508 | 2026-02-19 | 2026-07-23 |
Showing 20 of 268. Sign in to see all of them.
Breast Neoplasms (72) · Colorectal Neoplasms (27) · Neoplasm Metastasis (27) · Prostatic Neoplasms (18) · Neoplasms (14) · Squamous Cell Carcinoma of Head and Neck (14) · Colonic Neoplasms (11) · Adenocarcinoma (10) · Head and Neck Neoplasms (10) · Rectal Neoplasms (10) · Triple Negative Breast Neoplasms (10) · Carcinoma, Hepatocellular (8) · Carcinoma, Renal Cell (7) · Lung Neoplasms (7) · Recurrence (7)
Fluorouracil (32) · Radiotherapy (27) · Oxaliplatin (25) · Cisplatin (23) · Leucovorin (21) · Docetaxel (18) · Capecitabine (17) · Cyclophosphamide (16) · Paclitaxel (14) · Irinotecan (13) · Epirubicin (12) · Bevacizumab (11) · Chemotherapy, Adjuvant (10) · Drug Therapy (10) · Trastuzumab (10)
France (255) · Belgium (23) · Spain (23) · Italy (17) · United Kingdom (15) · Germany (13) · Netherlands (11) · Switzerland (11) · Ireland (7) · Denmark (6) · Poland (6) · Portugal (6) · United States (6) · Canada (5) · Martinique (5)
Julien Edeline, MD (3) · Michel Ducreux, MD, PhD (3) · Thomas Bachelot, MD (3) · Barbara Pistilli, MD (2) · Barbara Pistilli, MD, PhD (2) · Bertrand Tombal, Prof (2)
PMID 25592642, PMID 31401903, PMID 36882736, PMID 36884035, PMID 40845255, PMID 11181777, PMID 12954578, PMID 15014181, PMID 15171047, PMID 15368961, PMID 16009952, PMID 16376489, PMID 16382061, PMID 16394300, PMID 16485159, PMID 16622123, PMID 16730270, PMID 16801631, PMID 17200148, PMID 17267326, PMID 17301074, PMID 17307102, PMID 17416765, PMID 17492927, PMID 17510208, PMID 17635951, PMID 17679725, PMID 17762237, PMID 17785765, PMID 17912636, PMID 17998546, PMID 18037940, PMID 18048817, PMID 18083065, PMID 18191265, PMID 18269782, PMID 18279765, PMID 18332471, PMID 18809609, PMID 18981464, PMID 19096768, PMID 19179549, PMID 19190154, PMID 19243946, PMID 19318651, PMID 19474112, PMID 19528136, PMID 19692688, PMID 19751997, PMID 19917839
2025 (17), 2016 (9), 2018 (8), 2017 (7), 2023 (7), 2009 (5), 2014 (5), 2005 (4), 2019 (4), 2008 (2), 2004 (1), 2015 (1), U10CA180821 (1)